Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2025.068238
Journal Menu
Special Issues
Table of Content

All issues

Online First

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

REVIEW

Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective

Ashok Kumar Sah1,*, Ranjay Kumar Choudhary1,2, Velilyaeva Alie Sabrievna3, Karomatov Inomdzhon Dzhuraevich4, Anass M. Abbas5, Manar G. Shalabi5, Nadeem Ahmad Siddique6, Raji Rubayyi Alshammari7, Navjyot Trivedi8, Rabab H. Elshaikh1
1 Department of Medical Laboratory Sciences, College of Applied & Health Sciences, A Sharqiyah University, Ibra, 400, Oman
2 School of Allied Health Sciences, Sanskaram University, Jhajjar, 124108, Haryana, India
3 Department of Psychiatry, Medical Psychology and Narcology, Samarkand State Medical University, Samarqand, 140100, Republic of Uzbekistan
4 Department of Folk Medicine and Professional Diseases, Bukhara State Medical Institute, Bukhara, 200118, Republic of Uzbekistan
5 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, 72388, Saudi Arabia
6 Department of Pharmaceutical Chemistry, University of Hafar Al Batin, Hafar Al Batin, 31991, Saudi Arabia
7 Department of Pharmacy Practice, University of Hafar Al Batin, Hafar Al Batin, 31991, Saudi Arabia
8 Department of Physiotherapy, University Institute of Allied Health Sciences, Chandigarh University, Mohali, 140413, Punjab, India
* Corresponding Author: Ashok Kumar Sah. Email: email
(This article belongs to the Special Issue: Advances in Pathology, Early Diagnosis and Therapeutic Strategies for Breast Cancer)

Oncology Research https://doi.org/10.32604/or.2025.068238

Received 23 May 2025; Accepted 17 October 2025; Published online 14 November 2025

Abstract

Male breast cancer (MBC) is rare, representing 0.5%–1% of all breast cancers, but its incidence is increasing due to improved diagnostics and awareness. MBC typically presents in older men, is human epidermal growth factor receptor 2 (HER2)-negative and estrogen receptor (ER)-positive, and lacks routine screening, leading to delayed diagnosis and advanced disease. Major risk factors include hormonal imbalance, radiation exposure, obesity, alcohol use, and Breast Cancer Gene 1 and 2 (BRCA1/2) mutations. Clinically, it may resemble gynecomastia but usually appears as a unilateral, painless mass or nipple discharge. Advances in imaging and liquid biopsy have enhanced early detection. Molecular mechanisms involve hormonal signaling, HER2/epidermal growth factor receptor (EGFR) pathways, tumor suppressor gene alterations, and epigenetic changes. While standard treatments mirror those for female breast cancer, emerging options such as cyclin-dependent kinase 4 and 6 (CDK4/6), and poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and precision medicine are reshaping management. Incorporating artificial intelligence, molecular profiling, and male-specific clinical trials is essential to improve outcomes and bridge current diagnostic and therapeutic gaps.

Keywords

Male breast cancer; epidemiology; diagnostic strategies; molecular profiling; therapeutic advances; precision oncology; prognostic biomarkers; multiomics; personalized medicine

  • 247

    View

  • 54

    Download

  • 0

    Like

Related articles
Copyright© 2025 Tech Science Press
© 1997-2025 TSP (Henderson, USA) unless otherwise stated

Share Link